Cancer – Page 3 – HealthQuill

Pfizer is expected to close the $43 billion acquisition of Seagen by Thursday as the company announced restructuring its business and management.

Pfizer revamps organisation as $43 billion Seagen deal comes to close

HQ Team December 13, 2023: Pfizer is expected to close the $43 billion acquisition of Seagen by Thursday as the company announced restructuring.

by HealthQuill
December 13, 2023
0 Comments

2023: Bristol Myers Squib will pay a total of $8.4 billion to SystImmune Inc., the US arm of Chinese drugmaker Sichuan Biokin Pharmaceutical Co., to jointly develop and market a cancer drug outside China.

Drugs Health Pharma

Bristol Myer to pay China’s drugmaker Sichuan $8.4b to develop cancer drug

HQ Team December 12, 2023: Bristol Myers Squib will pay a total of $8.4 billion to SystImmune Inc., the US arm of Chinese.

by HealthQuill
December 12, 2023
0 Comments

Drugs Health Pharma

Opinion: HPV, cervical cancer, women and vaccination

By K. Leelamoni December 12, 2023: The Human Papilloma Virus (HPV) is the name of a group of viruses of 200 known viruses..

by HealthQuill
December 12, 2023
1 Comment

AbbVie Inc., operating in therapeutic areas such as immunology, oncology, neuroscience, and eye care, announced a pact to acquire ImmunoGen, Inc., for $10.1 billion. Image Credit: AbbVie

Drugs Health Pharma

AbbVie to buy Immunogen for $10.1b to expand solid tumour market

HQ Team November 30, 2023: AbbVie Inc., operating in therapeutic areas such as immunology, oncology, neuroscience, and eye care, announced a pact to.

by HealthQuill
November 30, 2023
0 Comments

India’s Immunoactive Cell Therapy Ltd., has got a marketing authorisation from the drug regulator for a therapy to treat leukaemia and cancer of the lymphatic system.

Drugs Health Pharma

ImmunoACT gets nod for leukaemia, lymphoma cancer therapy in India

HQ Team October 16, 2023: India’s Immunoactive Cell Therapy Ltd., has got a marketing authorisation from the drug regulator for a therapy to.

by HealthQuill
October 16, 2023
0 Comments

Eli Lilly and Company announced its experimental drug for treating severe Crohn's disease met secondary targets in efficacy and safety.

Drugs Health Pharma

Eli Lilly late-stage trial drug for Crohn’s disease meets testing goals

HQ Team October 13, 2023: Eli Lilly and Company announced its experimental drug for treating severe Crohn’s disease met secondary targets in efficacy.

by HealthQuill
October 13, 2023
0 Comments

The Food and Drug Administration has approved Pfizer Inc.’s treatment for metastatic non-small cell lung cancer.

Drugs Health Pharma

FDA nod for Pfizer’s combination therapy for non-small cell cancer

HQ Team October 12, 2023: The Food and Drug Administration has approved Pfizer Inc.’s treatment for metastatic non-small cell lung cancer. The FDA.

by HealthQuill
October 12, 2023
0 Comments

Egypt has been granted a “gold tier” status by the WHO for providing 93% of those diagnosed with hepatitis C with treatment in its path to eliminate the infection.

Drugs Health Pharma

Egypt close to ending hepatitis C, gets WHO ‘gold tier’ status

HQ Team October 9, 2023: Egypt has been granted a “gold tier” status by the WHO for providing 93% of those diagnosed with.

by HealthQuill
October 9, 2023
0 Comments

Bristol Myers Squibb, one of the world’s largest pharmaceutical companies, will acquire Mirati Therapeutics for $5.8 billion through a combination of cash and debt to broaden its cancer portfolio.

Drugs Health Pharma

Bristol Myers acquires Mirati Therapeutics for $5.8 billion

HQ Team October 9, 2023: Bristol Myers Squibb, one of the world’s largest pharmaceutical companies, will acquire Mirati Therapeutics for $5.8 billion through.